Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations
July 02 2024 - 8:00AM
Bionano Laboratories, a clinical laboratory services business of
Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical
genome mapping (OGM) will be featured in three scientific
presentations at the 2024 joint annual meeting for the American
Society for Clinical Laboratory Science (ASCLS), the Association of
Genetic Technologists (AGT), and the Society of American Federal
Medical Laboratory Scientists (SAFMLS). The conference, which
brings together laboratory professionals and industry partners
affiliated with three professional societies for networking and
educational sessions focused on chemistry, microbiology,
hematology, molecular diagnostics and cytogenetics, will be held
July 8-12, 2024, in Pittsburgh, Pennsylvania and online.
At a sponsored scientific workshop titled
“Revolutionizing hematological disease: unraveling genomic
mysteries with optical genome mapping,” Su Yang, CG (ASCP), from
The University of Texas MD Anderson Cancer Center, will present
cancer research case studies that demonstrate OGM’s ability to
detect structural abnormalities in hematological samples at high
sensitivity and resolution.
A session titled “Clinical utilities of optical
genome mapping at clinical cytogenetic labs,” led by Ying Zhou, MD,
PhD, FACMG, of The Johns Hopkins University School of Medicine,
will cover the ability of the OGM workflow to detect structural and
copy number variants relevant to cancer research.
Wahab Khan, PhD, FACMG, from Dartmouth Hitchcock
Medical Center, will present at a session titled “Setting up
optical genome mapping in your cytogenetic laboratory: points for
consideration in analysis and test validation,” where he will cover
the implementation and validation of OGM for cancer cytogenetic
research applications.
Session |
Title |
Presenter |
Presented |
Sponsored Workshop |
Revolutionizing Hematological Disease: Unraveling Genomic Mysteries
with Optical Genome Mapping |
Yang S. |
July 9, 20248:00-11:00 AM EDTGrand Ballroom 3 |
Educational Session |
Clinical Utilities of Optical Genomic Mapping at Clinical
Cytogenetic Labs |
Zhou Y. |
July 10, 20244:00-5:00 PM EDTGrand Ballroom 4 |
EducationalSession |
Setting up Optical Genome Mapping in your Cytogenetic Laboratory:
Points for Consideration in Analysis and Test Validation |
Khan W. |
July 11, 20241:30-2:30 PM EDTGrand Ballroom 3 |
“We are pleased to see a number of sessions at
this joint conference from leading medical centers that highlight
OGM as a cutting-edge tool for molecular and cytogenetic research,
due to its high sensitivity and resolution and simple workflow. We
believe laboratory professionals across the globe will continue to
adopt and utilize the OGM workflow due to its potential to
positively impact cancer and other research applications,”
commented Erik Holmlin, PhD, president and chief executive officer
of Bionano.
More details on the conference can be found here.
About Bionano Laboratories:
Bionano Laboratories provides access to genetic
answers and support utilizing cutting-edge technologies to advance
the way the world sees the genome. Its clinical diagnostics
services offer optical genome mapping (OGM) testing that combines a
comprehensive testing portfolio with thoughtful and accessible
support options. Bionano Laboratories also offers direct access to
OGM for applications across basic, translational and clinical
research. For more information, visit
www.bionanolaboratories.com
About Bionano
Bionano is a provider of genome analysis
solutions that can enable researchers and clinicians to reveal
answers to challenging questions in biology and medicine. The
Company’s mission is to transform the way the world sees the genome
through optical genome mapping (OGM) solutions, diagnostic services
and software. The Company offers OGM solutions for applications
across basic, translational and clinical research. The Company also
offers an industry-leading, platform-agnostic genome analysis
software solution, and nucleic acid extraction and purification
solutions using proprietary isotachophoresis (ITP) technology.
Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the
Company also offers OGM-based diagnostic testing services.
For more information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “ability,” “believe,”
“potential,” “will,” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, OGM’s ability to
detect pathogenic structural and copy number variants relevant to
hematological cancer research; OGM’s ability to detect structural
abnormalities in hematological samples at high sensitivity and
resolution; OGM’s utility across cancer cytogenetic research
applications; the utility of OGM for research in the areas reported
in the presentations given and the posters made available at the
2024 joint annual meeting for ASCLS, AGT, and SAFMLS, and the
growth and adoption of OGM for use in hematologic research
applications. Each of these forward-looking statements involves
risks and uncertainties. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: global and macroeconomic
events, such as recent and potential bank failures, supply chain
disruptions, global pandemics, inflation, and the ongoing conflicts
between Ukraine and Russian and Israel and Hamas, on our business
and the global economy; general market conditions; changes in the
competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; failure of
OGM’s ability to detect pathogenic structural and copy number
variants relevant to hematological cancer research; failure of
OGM’s ability to detect structural abnormalities in hematological
samples at high sensitivity and resolution; failure of OGM’s
utility across cancer cytogenetic research applications; failure of
researchers to adopt OGM; failure of our OGM solutions to offer the
anticipated benefits for and contributions to the areas reported in
the presentations given and posters made available at the 2024
joint annual meeting for ASCLS, AGT, and SAFMLS; future study
results contradicting the results reported in the presentations
given and posters made available at the 2024 joint annual meeting
for ASCLS, AGT, and SAFMLS; changes in our strategic and commercial
plans; our ability to obtain sufficient financing to fund our
strategic plans and commercialization efforts; our ability to
effectively manage our uses of cash, and our ability to continue as
a “going concern”; the ability of medical and research institutions
to obtain funding to support adoption or continued use of our
technologies; and the risks and uncertainties associated with our
business and financial condition in general, including the risks
and uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2023 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:
David HolmesGilmartin Group+1 (858) 888-7625IR@bionano.com